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Transcriptional proﬁling of breast cancer-associated lymphatic
vessels reveals VCAM-1 as regulator of lymphatic invasion and
permeability
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Tumor-associated lymphangiogenesis and lymphatic invasion of tumor cells correlate with poor outcome in many tumor types,
including breast cancer. Various explanations for this correlation have been suggested in the past, including the promotion of
lymphatic metastasis and an immune-inhibitory function of lymphatic endothelial cells (LECs). However, the molecular features
of tumor-associated lymphatic vessels and their implications for tumor progression have been poorly characterized. Here, we
report the ﬁrst transcriptional analysis of tumor-associated LECs directly isolated from the primary tumor in an orthotopic
mouse model of triple negative breast cancer (4T1). Gene expression analysis showed a strong upregulation of inﬂammation-
associated genes, including endothelial adhesion molecules such as VCAM-1, in comparison to LECs derived from control
tissue. In vitro experiments demonstrated that VCAM-1 is not involved in the adhesion of tumor cells to LECs but unexpectedly
promoted lymphatic permeability by weakening of lymphatic junctions, most likely through a mechanism triggered by
interactions with integrin α4 which was also induced in tumor-associated LECs. In line with this, in vivo blockade of VCAM-1
reduced lymphatic invasion of 4T1 cells. Taken together, our ﬁndings suggest that disruption of lymphatic junctions and
increased permeability via tumor-induced lymphatic VCAM-1 expression may represent a new target to block lymphatic
invasion and metastasis.
Introduction
Tumor-associated lymphangiogenesis and lymphatic expansion
are common phenomena in many tumor types, and frequently
correlate with metastasis and poor outcome.1,2 Typically, they
affect the primary tumor tissue as well as draining collecting ves-
sels and lymph nodes (LNs) which can markedly increase in size
during tumor progression.3 In addition, lymphangiogenesis may
also occur at distant metastatic sites, where it correlates with poor
outcome in patients with melanoma metastasis to the lung.4 With
regard to breast cancer, clinical studies have revealed that the
extent of lymphangiogenesis is very heterogenous, as is the corre-
lation with the clinical outcome,1,2 probably reﬂecting the wide
spectrum of breast cancer subtypes which differ extensively in
their cellular, molecular and pathological characteristics and prog-
nosis. Nonetheless, a recent meta-analysis including a total of
19 clinical studies involving various breast cancer subtypes found
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an overall positive correlation between lymphatic vessel density,
lymphatic invasion and reduced disease-free and overall survival.5
There are several potential explanations for this correlation.6
First, tumor- (or metastasis-) associated lymphatic vessels are
directly involved in LN metastasis, which can give rise to distant
metastasis both in tumor models and in cancer patients.7–11 A
critical step toward lymphatic metastasis is the invasion of tumor
cells into tumor-associated lymphatic vessels. Consequently, the
presence of lymphatic invasion also correlates with poor out-
come.1,2 In addition, lymphatic vessels have been proposed to
serve as a niche for stem-like cancer cells that may promote
recurrence after phases of dormancy.12 Finally, lymphatic endo-
thelial cells (LECs), especially those lining the lymphatic sinuses
of LNs, have been implicated in the inhibition of adaptive T-cell
immunity through various mechanisms including antigen pre-
sentation and expression of coinhibitory molecules, such as PD-
L1 (reviewed in Ref. 13).
Despite the multiple roles of the lymphatic system in cancer
progression, surprisingly little is known about the molecular
changes occurring in tumor-associated lymphatic vessels that may
explain their tumor-promoting function and could reveal new tar-
gets for cancer therapy. So far, only few studies have investigated
gene expression signatures of tumor-associated lymphatic endo-
thelium, including tumor-derived, in vitro expanded LECs,14
tumor-associated lymphatic collectors15 and LECs isolated from
tumor-draining LNs.16 Correspondingly, the mechanisms regulat-
ing lymphatic invasion of tumor cells are still not fully understood.
It has been suggested that chemokines and adhesion molecules
expressed by tumor-associated LECs are involved in this
process,14,17–19 indicating that at least in some cases, cancer cells
may employ similar pathways as leukocytes to enter lymphatic
vessels. On the other hand, lymphatic invasion may also be medi-
ated by high levels of lymphangiogenic signaling leading to poor
lymphatic vascular integrity,20 by destruction of lymphatic endo-
thelium by tumor cells21 or by bystander cells such as ﬁbroblasts,22
innate lymphoid cells23 ormacrophages.24
Here, using an orthotopic, syngeneic mouse model of triple-
negative breast cancer (4T1), we report the ﬁrst gene expression
signature of LECs directly isolated from primary tumor tissue.
The upregulated genes were highly enriched for inﬂammation-
associated genes, such as adhesion molecules and chemokines.
Interestingly, both VCAM-1 and its receptor integrin α4 were
induced on tumor-associated LECs. We found that blockade of
VCAM-1 in vitro and in vivo reduces tumor-induced lymphatic
permeability and lymphatic invasion, suggesting that integrin
α4—VCAM-1 interactions among tumor-associated LECs could
be a potential new target to impede lymphatic metastasis.
Materials and Methods
Cell lines
4T1-luc2 cells (RRID:CVCL_L899, Caliper, Newton, MA) were
maintained in DMEM with L-glutamine and 10% FBS (all
Thermo). B16-F10-luc2 cells (RRID:CVCL_5J17, Caliper)
expressing human VEGF-C25 were maintained in DMEM with
GlutaMax, pyruvate, 10% FBS and 1.5 mg/ml G418 (Roche,
Basel, Switzerland). Immortalized mouse LECs26 were
maintained on collagen type-1 (Advanced Biomatrix)/ﬁbronectin
(Millipore, Burlington, MA) coated dishes (10 μg/ml each) in
DMEM/F12 with 20% FBS, 56 μg/ml heparin (Sigma, St. Louis,
MO), and 10 μg/ml endothelial cell growth supplement (BioRad,
San Diego, CA). LECs were cultured at 33C in the presence of
1 U/ml IFN-γ (Peprotech, Rocky Hill, NJ) for maintenance, and
at 37Cwithout IFN-γ for experiments.
The CrispR-Cas9n double nickase approach was used to
generate VCAM-1 knockout clones of the 4T1-luc2 cell line as
described.27 In brief, a pair of guide-RNAs was designed for target
sequences in exon 3 of the mouse VCAM-1 gene (Fig. 3a) using
the online tool at http://crispr.mit.edu, and were cloned into
pSpCas9n(BB)-2A-GFP (Addgene #48140). Vectors were trans-
fected into 4T1-luc2 cells using polyethylenimine. Forty-eight
hours later, single GFP+ clones were sorted using an ARIAII sorter
(BD), expanded and screened for successful VCAM-1 knockout
by FACS and genomic PCR followed by sequencing. One clone
with complete loss of VCAM-1 protein expression and a con-
ﬁrmed deletion in exon 3 (1F8) was selected for all further experi-
ments. A clone transfected with pSpCas9n(BB)-2A-GFP without
guide-RNAs (XF9) was used as control.
All cell lines were routinely tested for mycoplasma contam-
ination using the Mycoscope kit (Genlantis, San Diego, CA).
Conditioned media
Conditioned media (CM) were collected from 4T1-1F8 cells
cultured for 72 hr in DMEM + 1% FBS. DMEM + 1% FBS
served as control. CM were centrifuged, ﬁltered (0.2 μm) and
stored at −80C until use. In some cases, CM were depleted
of tumor-cell secreted SPARC using goat anti-SPARC (R&D
AF942) coupled to protein-G dynabeads (Thermo) by O/N
incubation at 4C under constant rotation.
What’s new?
Tumor-associated lymphatic vessels serve important roles in tumor progression and metastasis. Nonetheless, little is known
about the molecular changes in these vessels that give rise to a tumor-promoting phenotype. In this study, transcriptional
analysis was performed on lymphatic endothelial cells (LECs) isolated from a mouse model of triple-negative breast cancer.
Endothelial adhesion molecules, including tumor-induced VCAM-1, were strongly upregulated in tumor-associated LECs.
Additional experiments showed that VCAM-1 upregulation inﬂuences lymphatic permeability and that its inhibition attenuates
lymphatic breast cancer cell invasion. The ﬁndings identify VCAM-1 as a potential target for the blockade of lymphatic invasion
of tumor cells.
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VCAM-1 blocking antibody
The rat antimouse VCAM-1 blocking antibody clone 6C7.1 (rat
IgG128) was generated in house by protein-G (GEHealthcare) puri-
ﬁcation from supernatant of hybridoma cells (a kind gift of Prof.
Dietmar Vestweber, MPI Münster) cultured in Hybridoma SFM
medium (Thermo) using the Äkta Start system (GE Healthcare,
Chicago, IL). Puriﬁed antibody was concentrated and rebuffered to
PBS, depleted of endotoxin using Detoxi-Gel columns (Thermo),
and sterile ﬁltered before use.
Mice and tumor models
All animal procedures were approved by the Cantonal Veterinary
Ofﬁce Zurich (license number ZH012/15). Balb/c and C57Bl6/N
mice (Janvier) were housed in an SPF facility. Parental 4T1-luc2 or
4T1-1F8 cells (1 × 105) were implanted into the 4th mammary fat
pad, and B16F10 cells (1 × 105) were injected intradermally into
the ﬂank. Tumors were allowed to grow for up to 3 weeks (4T1) or
2 weeks (B16F10), and the volume was monitored by caliper mea-
surements and calculated as vol = (length × width2 × π/6). For
ex vivo bioluminescence imaging, mice were i.p. injected with 3mg
luciferine/20 g body weight. Ten minutes later, mice were eutha-
nized and tumors, LNs, lung and liver were imaged separately in
an IVIS Spectrum instrument (Perkin Elmer, Waltham, MA). For
VCAM-1 blockade, 4T1-1F8 and B16F10-VEGFC tumor-bearing
mice were treated every other day with 100 μg of VCAM-1 block-
ing antibody (clone 6C7.1) or control rat IgG1 (BE0080, BioXCell,
West Lebanon, NH) by i.p. injection.
Sorting of tumor-associated LECs and RNA sequencing
Mice were euthanized on Day 21 after tumor implantation
and tumors together with the overlying skin were collected,
minced and digested in 10 mg/ml collagenase IV (Sigma),
20 μg/ml DNAse I and 2.25 μM CaCl2 for 30 min at 37C.
Abdominal skin from naïve mice served as control. The tissue
was passed through a 70 μm strainer, depleted of erythrocytes
using PharmLyse (BD), washed and ﬁltered through a 40 μm
cell strainer.
Cell suspensions were stained with CD45.2-FITC (BD 553772),
CD31-APC (BD 551262) and hamster antipodoplanin (clone
8.1.1, DSHB Iowa) followed by goat antihamster-PE (Thermo
HA6104) and labeling with 7-AAD (Biolegend, San Jose, CA) for
life/dead discrimination. LECs (CD45− CD31+ podoplanin+) were
sorted directly into RLT buffer (Qiagen, Hilden, Germany) using
an ARIA II sorter (BD), and stored immediately at −80C until
RNA extraction using the RNeasymicro kit (Qiagen). RNA quality
check, library preparation (Smart-seq ultra-low RNA input kit v2,
Clontech, Mountain View, MA) and RNA sequencing (2 × 50 bp
paired-end reads on a HiSeq 2500, Illumina) were performed
at the New York Genome Center (NYGC, nygenome.org)
according to the manufacturers’ protocols. Basic analysis (map-
ping, counting) was also performed at the NYGC. Differential gene
expression analysis byDESeq2 v1.22.129 was done in R v3.5.1 using
the corresponding packages from Bioconductor v3.8. Genes with a
false discovery rate (FDR) < 0.01 and a log2FC > 2 between control
skin and tumor-associated LECs were considered as differentially
expressed and are listed in Supporting Information Table S1. Gene
ontology BP (biological process) annotation was done using
DAVID 6.8 (david.ncifcrf.gov,30,31).
FACS analysis of tissues and cultured cells
Cell suspensions of control skin, 4T1 tumors and tumor-draining
LNs were prepared as described.32 For staining, the following
antibodies were used: CD45-APC/Cy7 or CD45-PaciﬁcBlue
(Biolegend 103116, 103126), CD31-APC (BD 551262), podoplanin-
PE (eBioscience, San Diego, CA, 12-5381-82), CD3-PE/Cy7
(Biolegend 100220), CD11b-BV605 (Biolegend 101257), Ly6C-
PE (Biolegend 128008), Ly6G-FITC (Biolegend 127606), F4/80-
Alexa647 (BioRad MCA497G), VE-cadherin-APC (Biolegend
138012) and goat antimouse VCAM-1 (R&D AF643), followed
by washing and labeling with a secondary donkey antigoat-
Alexa488 antibody. For staining of cultured cells, cells were
harvested using trypsin and subsequently stained with Itga4-FITC
(Biolegend 103606), Itgb1-FITC (Biolegend 102206), goat anti-
mouse Itga9 (R&D, Minneapolis, MN, AF3827) or goat antimouse
VCAM-1 (R&D AF643), followed by a donkey antigoat-Alexa488
antibody. 7-AAD or Zombi-Aqua (both Biolegend) was used for
life/dead discrimination. Samples were analyzed on an ARIA II or
a Canto (both BD) or a Cytoﬂex S (Beckman Coulter, Brea, CA),
and analyzed using FlowJo v10.4.2 (FlowJo LLC, Ashland, OR).
Quantitative PCR
Monolayers of mouse LECs were starved O/N in DMEM/F12
+ 1% FBS and were subsequently treated with mouse VEGF-A
(20 ng/ml, Cell Sciences, Newburyport, MA), VEGF-C (200 ng/ml,
R&D), TNF-α (40 ng/ml, Peprotech), IFN-γ (100 ng/ml,
Peprotech) or 50% 4T1-1F8 CM or the corresponding control
medium. RNA was extracted at the indicated timepoints using the
NucleoSpin RNA kit (Macherey-Nagel, Düren, Germany), and
reverse transcribed using the high capacity cDNA synthesis kit
(Applied Biosystems, Foster City, CA). Quantitative real-time PCR
was performed on a 7900HT FAST instrument (Applied Bio-
systems) using SYBRGreen Master Mix (Roche), with mouse
RPLP0 serving as reference gene. The following primer sequences
were used: mRPLP0 fwd: AGATTCGGGATATGCTGTTGG, rev:
TCGGGTCCTAGACCAGTGTTC; mVCAM1 fwd: TGGG
AAGCTGGAACGAAGTA, rev: CTCTGGATCCTTGGGGAAA.
Adhesion assay
Monolayers of mouse LECs were starved O/N in 1% FBS in
DMEM/F12 and treated with TNF-α (40 ng/ml) for 24 hr. Subse-
quently, cells were treated with a VCAM-1 blocking antibody
(clone 6C7.1) or control rat IgG1 (both 25 μg/ml) for 1 hr. Tumor
cells were labeled using the PKH26 dye (Sigma) according to the
manufacturer’s instructions and were added to the treated LEC
monolayers for 15 min. Then, monolayers were washed with PBS
to remove nonadherent cells and ﬁxed in 4% PFA. Four micro-
scopic images around the center of each well were taken with an
inverted Axioskop 2 (Zeiss) with a 5× objective and the number of
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adherent labeled tumor cells was counted in Fiji.33 Three
wells/condition were analyzed within each individual experiment.
In vitro permeability assay
Mouse LECs were seeded on ﬁbronectin/collagen-coated transwell
inserts (0.4 μm pore size, Costar, Washington, DC) and starved
O/N in DMEM/F12 + 1% FBS with or without TNF-α (40 ng/ml,
Peprotech). The monolayers were subsequently treated with
VCAM-1 blocking antibodies (clone 6C7.1) or control rat IgG1
for 1 hr before the addition of 4T1-1F8 CM or control medium
for another 6 hr. The ﬁnal concentrations of antibody and CM
were 25 μg/ml and 50%, respectively. Next, transwell inserts were
transferred to wells with fresh medium and 70 kDa FITC-dextran
(Sigma) was added to the inner well to a ﬁnal concentration of
1 mg/ml. Samples from the outer well were taken at the indicated
timepoints and the amount of ﬂuorescence was measured using a
Gemini plate reader (Molecular Devices, San Jose, CA). Three
wells/condition were analyzed within each individual experiment.
Immunoﬂuorescence and immunohistochemistry
Immunoﬂuorescence staining of 7 μm cryosections of skin and
tumors was performed essentially as before.32 The following anti-
bodies were used: goat antimouse VCAM-1 (R&D AF643), rabbit
antimouse LYVE-1 (AngioBio, San Diego, CA, 11-034), goat
antimouse LYVE-1 (R&D AF2125), rat antimouse MECA32
(BD 553849), rabbit antipan-keratin (Dako Z0622), rabbit anti-
gp100 (abcam ab137078), goat antimouse VE-cadherin (R&D
AF1002), rat antimouse Itga4 (EMD Millipore CBL1304), goat
antimouse Itga9 (R&DAF3827), rat antimouse Itgb1 (BD 553715)
and corresponding secondary antibodies donkey antirabbit, anti-
goat and antirat conjugated to Alexa488 or Alexa594 (all Thermo,
Waltham, MA). Images were taken with an Axioskop 2, an
LSM780 or an LSM880 confocal microscope (all Zeiss). For ﬂuo-
rescence staining of cultured cells, LECmonolayers were treated as
described above, washed and ﬁxed in 4% PFA. Cells were stained
with goat antimouse VE-cadherin (R&D AF1002) in presence of
0.3% Triton X100 followed by a secondary donkey antigoat
Alexa594 antibody. Quantiﬁcation of the VE-cadherin positive
area was measured by manual thresholding in Fiji and normalized
to the number of nuclei/image (nuclei on edges were counted as
half). Immunohistochemistry was performed on sections of
formalin-ﬁxed, parafﬁn-embedded 4T1-1F8 tumors and tumor-
draining LNs. Sections were deparafﬁnized, followed by epitope
retrieval (10mMNa-citrate pH 6.0) and stainedwith a pan-keratin
antibody (Dako Z0622) followed by a goat antirabbit biotin sec-
ondary antibody and detection with the ABC kit and AEC sub-
strate (all Vector Laboratories, Burlingame, CA).
Statistical analysis
All data analyses apart from the RNA sequencing data were done
using Prism v8 (GraphPad Software Inc., San Diego, CA).
Bars/horizontal lines indicate mean values  standard deviations.
Student’s t-test (to compare two groups), one-way ANOVA
(to compare more than two groups) or two-way ANOVA
(to compare groups deﬁned by two variables) were used to test for
statistical signiﬁcance. A p-value < 0.05 was considered signiﬁcant.
Data availability
The entire sequencing data are available at the European Nucle-
otide Archive (ENA) under accession number PRJEB30889.
Other data will be made available upon reasonable request.
Results
Inﬂammation-related genes are upregulated in tumor-
associated lymphatic vessels
To investigate molecular changes in tumor-associated lymphatic
vessels, we employed the orthotopic 4T1 triple-negative breast
cancer model which spontaneously metastasizes to the lung and
displays robust peri- and intratumoral lymphangiogenesis
(Fig. 1a). Tumor cells were implanted into the fourth mammary
fat pad of wild-type Balb/c mice. Three weeks later, we collected
the tumors (including the thin overlying skin layer) and isolated
CD45− CD31+ podoplanin+ LECs by FACS sorting (Fig. 1b).
Abdominal skin from naïve Balb/c mice was used as control. On
average, we could isolate around 500 LECs/mouse, which were
then subjected to RNA sequencing. Due to the extremely low RNA
input and some unavoidable RNA degradation which led to a 30
bias in the mapped reads, only the 30 ends of the detected tran-
scripts (500 bp) were used for all further analyses, including a total
of four control and ﬁve 4T1 tumor-associated LEC samples. Of
note, expression of pan-endothelial markers such as CD31
(Pecam1), VE-cadherin (Cdh5) and VEGFR-2 (Kdr) as well as
lymphatic markers such as VEGFR-3 (Flt4), podoplanin (Pdpn),
Prox1 and CCL21 was robust in all samples and not signiﬁcantly
altered between the groups, whereas CD45 (Ptprc) was hardly
detectable, indicating that the isolation of LECs had been effective
(data not shown). Differential gene expression analysis resulted in
the identiﬁcation of 831 genes that were signiﬁcantly upregulated,
and 92 genes that were signiﬁcantly downregulated in tumor-
associated LECs (FDR < 0.01, log2FC > 2; Fig. 1c and Supporting
Information Table S1). Gene ontology (GO) analysis suggested
that the upregulated genes were highly enriched in transcripts
associated with inﬂammation, chemotaxis and immune-related
processes (Fig. 1d), including various chemokines as well as cell
adhesion molecules such as VCAM-1, GLYCAM and ALCAM
(Supporting Information Table S1).
VCAM-1 and integrin α4 are upregulated by tumor-
associated LECs
We were particularly intrigued by the generally high expression
level and strong upregulation (log2FC > 10) of VCAM-1, which
is typically considered as a leukocyte-to-endothelial adhesion
molecule. However, in line with a previous study,34 our RNA
sequencing data demonstrated that tumor-associated LECs also
upregulated integrin α4 (Itga4), and constitutively expressed high
levels of integrin α9 and β1 (Itgb1) (Supporting Information
Table S1). As integrin α4/β1 and α9/β1 are canonical VCAM-1
receptors, this suggested that lymphatic VCAM-1 may also have
Dieterich et al. 2807
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an LEC autonomous function, mediating interactions between
neighboring LECs that could inﬂuence lymphatic function. To
investigate this hypothesis further, we ﬁrst investigated expression
of VCAM-1 and its receptors on tumor-associated LECs on the
protein level. Immunoﬂuorescence staining of 4T1 tissue sections
revealed a strong VCAM-1 expression by 4T1 tumor cells them-
selves as previously published35 (Supporting Information Fig. S1a),
which made it difﬁcult to assess the expression of VCAM-1 in
LECs using this approach. On the other hand, α4, α9 and β1
integrins could be readily detected in 4T1-associated LECs, and
integrin α9 was also expressed in LECs in control abdominal skin
(Supporting Information Fig. S1b). In order to conﬁrm the
expression of VCAM-1 in tumor LECs, we therefore used ﬂow
cytometry and found that on Day 21 after tumor inoculation,
VCAM-1 was strongly induced in tumor LECs compared to
control abdominal skin LECs (Fig. 2a). No difference in VCAM-1
Figure 1. Transcriptional characterization of tumor-associated lymphatic vessels in the 4T1 breast cancer model. (a) Representative images of
abdominal skin of a naïve Balb/c mouse (top) and of a 4T1 tumor-bearing mouse (bottom), showing lymphatic vessels stained for LYVE-1 (red).
Dermal/peritumoral lymphatic vessels are marked with asterisks, intratumoral lymphatic vessels with an arrow. (b) Representative FACS plots of
control abdominal skin (top) and 4T1 tumor (bottom) single-cell suspensions (pregated for living singlets) to illustrate the strategy for sorting of
LECs. (c) Representation of RNA sequencing results of four control skin and ﬁve 4T1 tumor samples. Red dots indicate signiﬁcantly (FDR < 0.01,
log2FC > 2) differentially expressed genes in tumor-associated LECs compared to control LECs. (d) Gene Ontology analysis (biological process) of
signiﬁcantly up-regulated genes in 4T1-associated LECs compared to control skin LECs. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
2808 Tumor-induced lymphatic VCAM-1 mediates invasion and permeability
Int. J. Cancer: 145, 2804–2815 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
T
um
or
Im
m
un
ol
og
y
an
d
M
ic
ro
en
vi
ro
n
m
en
t
expression in draining LN LECs could be detected by FACS
(Supporting Information Fig. S1c). We made very similar observa-
tions in a second, unrelated tumor model. In B16F10 tumors
engineered to overexpress VEGF-C in order to increase the
amount of tumor-associated LECs,25 we found increased VCAM-1
expression in LECs within the primary tumor, but not in the
draining LN (Supporting Information Figs. S1d and S1e).
VCAM-1 in LECs is regulated by inﬂammatory cytokines
To characterize how VCAM-1 is regulated in LECs, we used an
in vitro system of immortalized mouse LECs,26 which we treated
with a panel of tumor-relevant (lymph-) angiogenic growth factors
and inﬂammatory cytokines, namely VEGF-C, VEGF-A, TNF-α
and IFN-γ. Using qPCR, we found that only TNF-α and, to a lesser
extent, IFN-γ induced VCAM-1 in cultured LECs (Fig. 2b). This
was conﬁrmed by FACS (Fig. 2c). VCAM-1 expression was also
induced when cultured LECs were exposed to conditioned
medium (CM) of 4T1 cells (Figs. 2d and 2e), which is known to
contain several inﬂammatory cytokines.36
Generation of a VCAM-1 knockout 4T1 clone
Targeting lymphatic VCAM-1 to assess its in vivo function is
difﬁcult in the context of a primary tumor that itself expresses
high levels of VCAM-1. We therefore genetically deleted
VCAM-1 in parental 4T1 cells by targeting two adjacent PAM
motifs in exon 3 with the help of speciﬁc guide RNAs and the
double nickase (Cas9n) approach to minimize off-target muta-
tions (Fig. 3a). After transfection, we selected tumor cell clones
with reduced VCAM-1 expression and analyzed them by geno-
mic PCR, sequencing and ﬂow cytometry. One of these clones,
designated as 1F8, displayed a deletion in exon 3 starting at the
targeted genomic site (data not shown) and had lost VCAM-1
protein expression entirely (Fig. 3b). Primary tumors formed
after orthotopic implantation of this clone grew at a comparable
rate to parental 4T1 tumors (Supporting Information Fig. S1f)
and still induced VCAM-1 expression in tumor-associated LECs
(Fig. 3c). Therefore, this clone was chosen for functional experi-
ments in vivo.
VCAM-1 blockade in vivo reduces lymphatic invasion of
tumor cells
To investigate the function of lymphatic VCAM-1 during tumor
progression, we inoculated syngeneic Balb/c mice with VCAM-1
deﬁcient 4T1-1F8 tumor cells and treated them every other day
with a VCAM-1-blocking antibody for 21 days. Previously, it has
been suggested that VCAM-1 is involved in tumor angiogenesis in
breast cancer.37 However, in our model, there was no measurable
effect on tumor angiogenesis, lymphangiogenesis, or blood vessel
permeability at the endpoint (Day 21) (Supporting Information
Fig. S2a–S2c). Additionally, VCAM-1 blockade had no major
effect on leukocyte inﬁltration into the tumor (Supporting Infor-
mation Fig. S2d). In line with this, we did not observe a signiﬁcant
impact on primary tumor growth, although 3 out of 10 anti-
VCAM-1 treated mice developed only very small tumors (Figs. 4a
and 4b). We also assessed the weight of tumor-draining inguinal
and axillary LNs. Although statistically not signiﬁcant, there was a
clear tendency toward smaller LNs in anti-VCAM-1 treated mice
compared to control rat IgG1 treated mice (Fig. 4c). A reduction
in draining LNweight could be due to various reasons, including a
reduction of lymphatic metastasis, lymphatic drainage or immune
cell recruitment via high endothelial venules. Therefore, we next
assessed the invasion of tumor cells into the tumor-associated
lymphatic vasculature within the primary tumor. Importantly, the
frequency of tumor-cell containing lymphatic vessels was signiﬁ-
cantly reduced on Day 21 after anti-VCAM-1 antibody treatment
(Fig. 4d). A similar trend was also observed at an earlier timepoint
Figure 2. VCAM-1 is upregulated on tumor-associated LECs in vivo
and by inﬂamed LECs in vitro. (a) Left panel: Representative FACS
histogram of VCAM-1 expression on 4T1-associated LECs (black
curve) compared to control skin LECs (gray curve) on day 21 after
tumor implantation. The gray dotted line indicates staining with
control goat IgG. Right panel: Quantiﬁcation of VCAM-1 expression
by FACS in control skin and 4T1-associated LECs (n = 4 mice/group;
one out of two independent experiments with equivalent results is
shown). (b) Immortalized mouse LECs were treated with the
indicated growth factors or cytokines for 6, 24 or 48 hr, and the
expression of VCAM-1 mRNA was determined by qPCR (n = 3
technical replicates; one representative of three independent
experiments is shown). (c) Upregulation of surface VCAM-1 on TNF-α
and IFN-γ treated mouse LECs was validated by FACS after 24 hr
(n = 3). (d) Cultured mouse LECs were treated with control medium
or 4T1 tumor cell-conditioned medium (CM, 50%) for the indicated
time periods before qPCR analysis of VCAM-1 mRNA expression
(n = 3 technical replicates; one representative of three independent
experiments is shown). (e) Upregulation of surface VCAM-1 on 4T1
CM treated mouse LECs was validated by FACS after 24 hr (n = 3;
*p < 0.05; **p < 0.01; ***p < 0.001).
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(Day 8), although it did not yet reach statistical signiﬁcance due to
an overall lower rate of lymphatic invasion at this timepoint
(Supporting Information Fig. S2e). Additionally, we also investi-
gated lymphatic invasion in mice bearing B16F10-VEGFC
tumors. However, lymphatic invasion was largely absent in this
model and was not affected by VCAM-1 blockade (Supporting
Information Fig. S2f).
4T1 cells have been reported to colonize tumor-draining LNs
very inefﬁciently.16,38–42 In line with this, with the exception of one
mouse, we were not able to detect LNmetastases in ourmodel, nei-
ther histologically nor by bioluminescence (Supporting Informa-
tion Figs. S2g and S2h), preventing us from further studying the
role of lymphatic VCAM-1 in lymphogenous metastasis. Distant
metastasis to lungs and liver was also low and not signiﬁcantly
affected by anti-VCAM-1 treatment (Supporting Information
Fig. S2i), most likely due to a critical function of 4T1-intrinsic
VCAM-1 in this process as reported previously.35
VCAM-1 regulates permeability of lymphatic vessels through
junction remodeling
We ﬁrst hypothesized that VCAM-1 expressed by LECs serves as
an adhesion molecule for tumor cells, facilitating their entry into
lymphatic vessels. However, using ﬂow cytometry, we found that
whereas 4T1-1F8 cells express high levels of integrin β1 (Itgb1),
they completely lacked the two α-chains α4 and α9 that are needed
to form the classic VCAM-1 receptors α4/β1 and α9/β1 (Fig. 5a).
This was in contrast to cultured mouse LECs which expressed all
three integrin chains in a largely TNF-independent manner, with
the exception of β1 which was slightly induced by TNF-α treat-
ment (Fig. 5b). In line with this, 4T1-1F8 cells adhered poorly to
mouse LEC monolayers in vitro, and neither TNF-α treatment of
the LECs (to induce VCAM-1 expression) nor VCAM-1 blockade
had any consistent effect on this adhesion (Fig. 5c). Interestingly,
the case was quite different for B16F10-VEGFC cells. In agreement
with a previous report,43 we found that these cells express high
levels of integrin α4, α9 and β1 (Supporting Information Fig. S3a),
and adhere to LEC monolayers in a TNF-α and VCAM-1 depen-
dentmanner (Supporting Information Fig. S3b).
We next hypothesized that VCAM-1 on LECs might be
involved in the organization of cell-to-cell junctions and in the reg-
ulation of permeability, as has been reported to be the case in blood
vessels.44–46 Indeed, using an in vitro permeability assay of mouse
LEC monolayers and a 70kD FITC-dextran tracer, we observed
that treatment with 4T1-1F8 CM increased permeability, which
could be entirely blocked by preincubation of the LECs with a
VCAM-1 blocking antibody (Fig. 5d). This effect required pre-
treatment of the LECs with TNF-α, most likely to induce sufﬁ-
ciently high levels of VCAM-1 (Supporting Information Fig. S3c).
Next, we aimed to elucidate the mechanisms of VCAM-1
dependent permeability regulation in LECs. Recently, it was
Figure 3. VCAM-1 is up-regulated in tumor-associated LECs in 4T1 tumors deﬁcient of VCAM-1. (a) Schematic representation of the strategy to delete
VCAM-1 in 4T1 tumor cells. Two neighboring PAMmotifs on the top and the bottom strandwere identiﬁedwithin exon 3 of the vcam1 gene (triangles).
Guide-RNAs for adjacent target sequences (in italics) together with the Cas9n enzymewere transfected into 4T1 tumor cells and single knockout clones
were isolated by FACS sorting. (b) Representative FACS histogram of VCAM-1 staining using a polyclonal antibody in a control clone (XF9) transfected
with Cas9n only and a complete VCAM-1 knockout clone (1F8). (c) 4T1-1F8 cells were implanted into Balb/cmice and the expression of VCAM-1 on
tumor-associated LECs was determined by FACS on Day 21 after implantation (n= 5mice/group; *p < 0.05).
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reported that the tumor-cell secreted protein SPARC can bind
VCAM-1 on blood vascular endothelial cells, activating an
intracellular signaling cascade leading to barrier disruption
and increased permeability.45 As 4T1 cells express SPARC
(data not shown), we hypothesized that a similar mechanism
might operate in LECs. However, antibody-mediated SPARC
depletion from the conditioned medium of 4T1-1F8 cells did
not reduce the permeability-reducing effect of VCAM-1
blockade, suggesting that SPARC did not play a major role in
this case (Supporting Information Fig. S3d).
Leukocyte binding to VCAM-1 on blood vessel endothelial
cells via integrin α4/β1 has also been reported to stimulate
junctional weakening by displacing ZO-146 and by reducing
VE-cadherin mediated cell adhesion via VE-PTP displacement
from VE-cadherin.44 Cultured mouse LECs expressed α4, α9 and
β1 integrins (Fig. 5b) and α4, together with VCAM-1, was
induced in 4T1-associated LECs (Supporting Information
Table S1). We therefore considered the possibility that LEC-LEC
interactions through α4/β1 and VCAM-1 could similarly induce
a weakening of lymphatic junctions, leading to increased
Figure 4. VCAM-1 blockade in vivo does not affect 4T1 tumor growth but inhibits lymphatic invasion. Tumor volumes (a) and endpoint (Day 21)
tumor weights (b) of VCAM-1 deﬁcient 4T1-1F8 tumors in mice treated with a VCAM-1 blocking antibody or a corresponding IgG control every
other day (n = 10 mice/group). (c) Weight of inguinal (left) and axillary (right) lymph nodes at the endpoint (Day 21; n = 10 mice/group).
(d) Left panel: Representative microscopic images showing frequent invasion of tumor cells (stained for pan-cytokeratin, red) into lymphatic
vessels (LYVE-1, green) in control-treated tumors but not in tumors treated with the VCAM-1 blocking antibody. Right panel: Quantiﬁcation of
the frequency of tumor cell-invaded lymphatic vessels in control and anti-VCAM-1 treated tumors (n = 10 control/9 treated tumors; *p < 0.05).
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Figure 5. VCAM-1 blockade reduces lymphatic permeability. (a, b) Representative FACS histograms (left panels) and staining quantiﬁcation (right
panels) of the classic VCAM-1 receptors integrin α4 (Itga4), integrin α9 (Itga9) and integrin β1 (Itgb1) in 4T1-1F8 cells (a) and cultured mouse
LECs with or without TNF-α treatment for 24 hr (b; n = 3). (c) Adhesion of ﬂuorescently labeled 4T1-1F8 cells to monolayers of cultured mouse
LECs pretreated with TNF-α or not and in the presence of control IgG or VCAM-1 blocking antibodies (n = 3 wells/condition; 1 representative of
6 individual experiments is shown). (d) In vitro permeability of mouse LEC monolayers grown on transwell inserts (0.4 μm pore size) toward 70 kD
FITC-dextran. LEC monolayers were pretreated with TNF-α overnight and subsequently incubated with control or 4T1 CM in presence of control IgG
or anti-VCAM-1 antibodies (n = 3 wells/condition; one representative of three individual experiments is shown). Statistical test refers to 4T1-1F8
CM—rat IgG1 compared to 4T1-1F8 CM—anti-VCAM-1. (e) Representative images (left panels) and quantiﬁcation (right panel) of VE-cadherin
staining in mouse LEC monolayers that were pretreated with TNF-α overnight and subsequently incubated with control or 4T1 CM in presence of
control IgG or anti-VCAM-1 antibodies (n = 10 random images/condition; *p < 0.05). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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permeability. To investigate this further, we stained cultured
LECs treated with TNF-α and 4T1-1F8 CM in the presence of a
VCAM-1 blocking or control rat IgG1 for VE-cadherin and
quantiﬁed brightly stained junctional areas. Doing so, we found
that VCAM-1 blockade increased junctional VE-cadherin
staining (Fig. 5e), whereas the total VE-cadherin level was not
affected (Supporting Information Fig. S3e). Interestingly, we
noted a trend towards increased VE-cadherin staining intensity
in LYVE-1+ lymphatic vessels in 4T1-1F8 tumors treated with
anti-VCAM-1, and towards a higher frequency of VE-cadherin+
LECs determined by FACS (Supporting Information Fig. S3f).
We also analyzed ZO-1 expression in cultured LECs treated with
4T1-1F8 and TNF-α but found no differences in the total protein
level or in its Ser-phosphorylation (Supporting Information
Fig. S3g). Taken together, these data indicate that tumor-derived
factors in combination with inﬂammatory signals induce
VCAM-1 and integrin α4 on tumor-associated LECs, leading to
a junctional displacement of VE-cadherin that increases perme-
ability and facilitates lymphatic invasion of tumor cells (Fig. 6).
Discussion
Despite their implication in tumor progression and correlation
with poor prognosis in many cancer types, the molecular features
of primary tumor-associated lymphatic vessels have remained
largely unknown, most likely due to the technical challenge to iso-
late sufﬁcient numbers of LECs from tumor tissue. The only previ-
ously reported gene expression signatures of tumor-associated
LECs were thus obtained from a VEGF-C-overexpressing tumor
model and involved in vitro expansion of LECs (which likely
affected their phenotype),14 concentrated on tumor-draining
lymphatic collectors,15 or on tumor-draining LNs.16 Using
FACS sorting of LECs in combination with an RNAseq proto-
col for ultra-low input, we provide here the ﬁrst complete and
direct transcriptional characterization of primary tumor-
associated lymphatic vessels in a model of triple-negative
breast cancer (4T1). Even with this approach, obtaining sufﬁ-
cient high-quality RNA was challenging, and some RNA deg-
radation could not be avoided due to the long and relatively harsh
digestion procedure required for both the tumor and the control
tissue. This was most likely the reason for a certain 30 bias we
observed among the mappable reads, which we mitigated by
including only the 30 ends (500 bp) of the transcriptome into the
differential gene expression analysis. Whereas this approach led
to the loss of information about the 50 regions, differential splic-
ing, etc., our dataset remains very valuable to study tumor-
induced gene expression changes in LECs.
Our results are striking in terms of the strong inﬂammatory gene
expression signature of 4T1-associated LECs, which included induc-
tion of many chemokines and adhesion molecules. We also found a
trend (log2FC = 1.96, FDR = 0.68) toward increased expression of
the T cell inhibitory protein PD-L1, which is in line with our own
previous observations.32 Clearly, this proinﬂammatory gene expres-
sion signature is likely to have a plethora of effects on tumor pro-
gression, metastasis and host immunity. Here, we focused on the
role of lymphatic VCAM-1. VCAM-1 is best known as adhesion
molecule mediating leukocyte adhesion and transmigration through
blood vessel endothelium under inﬂammatory conditions.47 Addi-
tionally, VCAM-1 expression has also been found on lymphatic ves-
sels during skin inﬂammation and has been reported to facilitate LN
migration of DCs48 and neutrophils.49
Besides its classic role in leukocyte-to-endothelial adhesion in
inﬂammatory situations, VCAM-1 expression by cancer cells has
been found to transmit survival signals for metastatic cells in the
lung (including 4T1 cells),35 and to facilitate LN colonization.50 In
line with this, we found a rather low rate of lung metastasis in mice
bearing VCAM-1 deﬁcient 4T1 tumors. VCAM-1 has furthermore
been implicated in breast cancer angiogenesis by mediating adhe-
sion between endothelial and perivascular cells37 as well as in the
regulation of blood vessel permeability in tumors and in associa-
tion with leukocyte diapedesis. Several mechanisms have been pro-
posed for this. Tichet et al.45 reported that melanoma cell-derived
SPARC binds to VCAM-1 on blood vessel endothelial cells, trig-
gering a signaling cascade that leads to actin remodeling and vascu-
lar barrier disruption. Furthermore, leukocyte binding to VCAM-1
via integrin α4/β1 was reported to destabilize endothelial junctions
via dissociation of the endothelial phosphatase VE-PTP from VE-
cadherin complexes44 and phosphorylation of ZO-1,46 leading to
Figure 6. Model of VCAM-1/integrin mediated permeability regulation
in tumor-associated lymphatic vessels. Schematic of the proposed
mechanism of how permeability and lymphatic invasion are
regulated through VCAM-1. Tumor-derived factors, in combination
with inﬂammatory signals from the tumor microenvironment, induce
expression of VCAM-1 and integrin α4 in associated LECs. VCAM-1
engagement by integrin α4/β1 or α9/β1 complexes on adjacent LECs
then acts on VE-cadherin complexes in LEC junctions and induces
their destabilization, possibly involving VE-PTP detachment from VE-
cadherin. This leads to the displacement of VE-cadherin from the
junctions, increasing paracellular permeability for tissue ﬂuid but
also facilitating tumor cell invasion into the lymphatic lumen. [Color
ﬁgure can be viewed at wileyonlinelibrary.com]
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loosening of endothelial junctions. Our data suggest that although
4T1 tumor cells express SPARC (data not shown), SPARC is not
involved in the regulation of lymphatic permeability, at least
in vitro. On the other hand, in agreement with a previous report
demonstrating that breast cancer-associated lymphatic vessels
upregulate integrin α4, possibly in response to lymphangiogenic
growth factors,34 we found that 4T1-associated LECs upregulate
integrin α4 and robustly expressed integrin α9, indicating that
LEC—LEC interactions via α4/β1 or α9/β1—VCAM-1 binding
might contribute to the regulation of lymphatic vessel permeability.
Finally, it is also possible that lymphatic VCAM-1 regulates vessel
permeability by recruiting immune cells releasing permeability-
inducing factors. Our data however indicate that VCAM-1 can
control LEC permeability independently of immune cells, at least
in vitro.
Our in vivo and in vitro results further suggest that VCAM-1
mediated permeability regulation involves reduction of junctional
VE-cadherin, possibly through a mechanism involving VE-PTP,
which according to our sequencing data is robustly expressed
by control and tumor-associated LECs (data not shown). It is
tempting to speculate that this pathway represents a mechanism
how lymphatic vessels are activated to take up more tissue ﬂuid in,
for example, inﬂammatory conditions, where increased liquid
ﬁltration from blood vessels requires increased lymphatic drainage
to keep tissue swelling at bay. In a tumor context, however,
increased lymphatic permeability and ﬂuid uptake likely come at
the cost of facilitated lymphatic invasion and dissemination of
tumor cells. In this regard, it is interesting to note that the
mechanism of VCAM-1 induced destabilization of VE-cadherin
complexes in endothelial junctions is highly related to the mecha-
nism of VEGF-A induced vessel permeability.44 Furthermore,
VEGF-C that activates similar intracellular signaling cascades as
VEGF-A was recently shown to destabilize VE-cadherin com-
plexes in lymphatic junctions in colorectal cancer, leading to
increased lymphatic invasion and metastasis.20 Thus, it appears
that both inﬂammatory signals (via induction of VCAM-1 and
integrin α4 in LECs) andVEGF signaling converge to increase per-
meability in lymphatic vessels via a reduction of VE-cadherin in
endothelial junctions. In line with this, lymphatic VCAM-1 block-
ade in the 4T1 model inhibited tumor cell lymphatic invasion and
appeared to reduce LN swelling. In agreement with our data,
blocking of α4/β1 integrin has previously been shown to reduce
LN metastasis in several mouse tumor models.34,50 Although this
was at least in part ascribed to an antilymphangiogenic effect of
α4/β1 blockade or to capture of VCAM-1+ tumor cells by LN
LECs, an inhibition of VCAM-1 mediated lymphatic permeability
might have contributed to those ﬁndings as well.
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